Overview

Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.

Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This study is aimed at assessing the safety and the efficacy of two dose regimens of recombinant human nerve growth factor (rhNGF) eye drops solution compared to vehicle for inducing a complete healing of stage 2 (persistent epithelial defect) and 3 (corneal ulcer) neurotrophic keratitis
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dompé Farmaceutici S.p.A
Treatments:
Mitogens
Ophthalmic Solutions
Pharmaceutical Solutions
Tetrahydrozoline